Summary
Introduction
Psoriasis is one of the most common chronic inflammatory diseases, affecting approximately 0Á5-1% of children and 2-3% of adults [1] . Although much effort has been focused upon seeking available anti-psoriatic drugs, there is currently no cure for psoriasis [2, 3] . Generally, it has been accepted that the development and progression of psoriasis are mediated by the cross-talk between keratinocytes and the host immune system, with many studies supporting a crucial role of the infiltration and cytokine production by pathogenic T cells in psoriatic skin lesions, which results in an excessively aberrant hyperproliferation and abnormal differentiation of keratinocytes [4] [5] [6] . Thus, deciphering the biology of host pathogenic T cells is critical for understanding the pathophysiological dysregulation of psoriasis. CD3 1 CD20 1 T cells are a group of CD3 1 T cells coexpressing T cell antigen CD3 and B cell antigen CD20 [7] . However, these cells do not express other classical B cell markers such as CD19 and immunoglobulin molecules, whereas a high level of surface interleukin (IL)-7 receptor, CD45RO, CD28 and CD27 and intracellular cytokines IL-17A, tumour necrosis factor (TNF)-a and interferon (IFN)-g expression could be observed. In addition, there is a rapid rise in the intracellular calcium concentration of these cells following treatment with anti-CD3 antibody, but not anti-immunoglobulin [8] . Therefore, CD3 
CD20
1 T cells display a T helper type 17 (Th17) feature and are involved in the pathogenesis of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis [9] [10] [11] [12] . Nevertheless, another study has found that CD3 
Materials and methods

Subjects and samples
Peripheral blood samples were obtained from 30 patients with psoriasis (male/female 5 19/11; average age 42Á1 6 13Á1 years; disease duration 13Á4 6 8Á5 years) in the Xinan Hospital of the Third Military Medical University. The patients had no other acute or chronic disease and did not take any medication for at least 1 month before enrolment into this study. Psoriasis Area and Severity Index (PASI) scores were used to measure the disease activity of patients, as described previously [14] . The PASI scores of 30 patients ranged from 3Á4 to 48Á8. Thirty healthy donors (male/female 5 18/12; average age 41Á8 6 12Á7 years) were enrolled as the control group. The Ethics Committee of Xinan Hospital, Third Military Medical University approved this study. Written informed consent was obtained from each subject. The clinical characteristics of patients with psoriasis are presented in Supporting information, Table S1 .
Antibodies and flow cytometry analysis
The following labelled antibodies were used to stain singlecell suspensions: anti-CD3 allophycocyanin (APC)-cyanin 7 (Cy7) (UCHT1), anti-CD20 peridinin chlorophyll (PerCP)-Cy5Á5 (2H7), anti-CD4 fluorescein isothiocyanate (FITC) (RPA-T4), anti-CD45RA FITC (HI100), anti-CD45RO FITC (UCHL1), anti-CD62L FITC (DREG-56), anti-CD69 FITC (FN50), anti-CD8 phycoerythrin (PE) (HIT8a), anti-CCR7 PE (G043H7), anti-CD38 PE (HB-7), anti-CD86 PE (IT2.2), anti-CD40 PE (HB14), anti-CD28 APC (CD28.2), anti-CD19 APC (HIB19), anti-human leucocyte antigen D-related (HLA-DR) APC (L243), anti-CD27 PE-Cy7 (O323), anti-IL-17A PE (BL168), anti-IL-4 APC (8D4-8) anti-IFN-g PE-Cy7 (4S.B3), anti-IL-21 APC (3A3-N2) and anti-TNF-a PE (MAB11) (Biolegend, San Diego, CA, USA). Fresh peripheral whole blood was incubated with lysing solution (BD Biosciences, San Jose, CA, USA) to lyse red blood cells and washed twice with phosphate-buffered saline (PBS), following incubation with surface antibodies for 30 min at 48C, and then fixed and permeabilized for 20 min using Cytofix/Cytoperm reagent (BD Biosciences). Next, the cells were washed twice with PBS containing 1% fetal calf serum (FCS) and then collected by flow cytometry with a FACSCanto II (BD Biosciences). Isotype-matched labelled antibodies were used to enable correct compensation and the antibodies specificity. For intracellular cytokine staining, peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of patients with psoriasis and healthy donors by Ficoll density gradient centrifugation (GE Healthcare, Shanghai, China), and PBMCs were then stimulated for 4 h with leucocyte activation cocktail, with BD GolgiPlug (BD Biosciences) before staining.
Statistical analysis
The results were summarized as the mean 6 standard error of the mean (s.e.m.) or median with interquartile range. Statistical analysis was performed using Prism version 5.0 software. Differences between the two groups of data were determined by two-tailed Student's t-test. When variance was detected, the Mann-Whitney U-test was used to analyse the difference between two groups. Multiple groups were analysed by one-way analysis of variance (ANOVA), as appropriate. Correlation analysis between the groups was evaluated by Spearman's correlation test. P < 0Á05 was accepted as statistically significant.
Results
Detection of circulating CD3
1 CD20
T cells in patients with psoriasis
Using flow cytometry, we first detected the prevalence of CD20 1 lymphocytes in the peripheral blood of patients with psoriasis. As shown in Fig. 1a ,b, we observed that total lymphocytes contained not only a substantial amount of CD3 -CD20 1 B cells (10Á1 6 0Á9%), but also a small frac- T cells in patients with psoriasis, and found that the majority of these cytokine-production CD3 1 CD20 1 T cells belonged to the CD45RO 1 subset (Supporting information, Fig. S4 ). Additionally, the CD4 1 subset produced higher levels of IL-17A, TNF-a and IL-21 than the CD8 1 subset, especially IL-17A-production CD3 1 CD20 1 T cells almost belonged to the CD4 1 subset (data not shown).
Increased IL-17A, TNF-a and IL-21-production circulating CD3 1 CD20 1 T cells correlated with disease severity in patients with psoriasis
To determine whether increased cytokine production of CD3
1
CD20
1 T cells were associated with disease severity, 
Discussion
Deciphering the function and clinical relevance of pathogenic T cells in psoriasis is critical for understanding how they affect the development and course of disease [15, 16] .
In the present study, we found that a subpopulation of CD3 1 CD20 1 T cells were characterized as activated effector cells in the peripheral blood of patients with psoriasis, and these cells produced high levels of proinflammatory cytokines that correlated with disease severity, implying that CD3 1 CD20 1 T cells might play a role in T cellmediated pathogenic immune response of psoriasis. It has been acknowledged that CD20 is expressed on the surface of B cells but not other cell lineages. However, the low level of CD20 expression on a subpopulation of human CD3 1 T cells was also reported [8, 17] . Later, one study doubted that this subset might be an artefact of flow cytometry [18] . Nevertheless, studies showed clearly that CD3 1 T cells expressed CD20 at the mRNA and protein levels by real-time polymerase chain reaction and confocal microscopy after sorting single cells, indicating the existence of the CD3 1 CD20 1 T cell subpopulation [12, 19] .
Consistent with these reports, our study also showed that a subpopulation of CD3 1 T cells expressed CD20 in the peripheral blood of patients with psoriasis and healthy donors at a similar level, and these cells lacked classical B cell markers CD19 and CD40. However, this subpopulation in patients with psoriasis contained more CD4 1 cells and fewer CD8 1 cells, whereas more CD8 1 cells and fewer CD4 1 cells of these cells were observed in healthy donors [7] , suggesting that the constitution of a CD4 1 and CD8
cells is altered in patients with
psoriasis. In particular, previous studies also showed that CD3 1 CD20 1 T cells were predominantly CD4 1 cells in patients with multiple sclerosis and rheumatoid arthritis [11, 19] ; we speculated that this phenomenon might exist in a variety of diseases. In addition, we also observed that more than half of circulating CD3 1 CD20 1 T cells in patients with psoriasis displayed an effector-memory phenotype, as they showed a higher level of T cells that lacked CD45RA (a marker of naive cells) and C-C chemokine receptor type 7 (CCR7) (a homing chemokine receptor of T cells to secondary lymphoid organs). However, these cells 
CD20
1 and CD3 1 CD20 -T cell subpopulations were gated, and then the levels of CD45RA 1 , CCR7
, HLA-DR 1 and CD40 1 cells in these two subpopulations were analysed (black: patients with psoriasis; grey: healthy donors). *P < 0Á05; **P < 0Á01; ***P < 0Á001. were still at the early-differentiation stage, as most of them expressed CD28 and CD27. We further analysed the activation status of circulating CD3 Although CD38 was also considered as one of the activation markers on T cells [20] , studies on infectious diseases donors. Each plot represents a single donor. Data were expressed as the mean 6 standard error of the mean. *P < 0Á05; **P < 0Á01; and ***P < 0Á001.
showed definitively that a subset of human T cells expressing HLA-DR but not CD38 have a particularly high ability to suppress the virus [21, 22] . Given the increased expression of HLA-DR on CD3 
-T cells [7, 9] , and a similar result was also observed in patients with psoriasis. Additionally, we found that CD3
1
CD20
1 T cells in patients with psoriasis produced higher levels of IL-17A, TNF-a and IL-21 than those in healthy donors, and these cytokine-production cells showed a significantly positive correlation with the severity of disease. Because IL-17A, TNF-a and IL-21 have been involved in the pathogenic process of psoriasis, and biological drugs targeting TNF-a and IL-17A in particular are used or undergoing clinical trials for the treatment of this disease [23] [24] [25] . Therefore, these results would highlight further the involvement of CD3 1 CD20 1 T cells in the pathogenesis of psoriasis. In summary, our study identified a subpopulation of circulating CD3
1 CD20 1 T cells in patients with psoriasis; their activated effector phenotype and a strong potential to cytokine production suggests a role of CD3 1 CD20 1 T cells in the pathogenesis of psoriasis. Given their proinflammatory ability, further study to elucidate the precise role of CD3 1 CD20 1 T cells in the pathogenic process of psoriasis is warranted. 
Supporting information
Additional Supporting Information may be found in the online version of this article at the publisher's website: Fig. S1 . Expression of CD19 on circulating CD3 
CD20
-T cells (Q3: blue) was analysed further. Fig. S2 . Expression of CD45RA and C-C chemokine receptor type 7 (CCR7) on circulating CD3
1
CD20
1 and CD3
1
CD20
-T cells in patients with psoriasis and healthy donors (control). Human peripheral whole blood from patients with psoriasis was stained with anti-CD3, anti-CD20, anti-CD45RA and anti-CCR7 antibodies or isotype controls. CD3
1
CD20
1 and CD3 1 CD20 -T cell subpopulations were gated from the lymphocyte defined by a forward-scatter (FSC) and side-scatter (SSC) dot-plot, and the expression of CD45RA and CCR7 in these two subpopulations was then analysed. **P < 0Á01. 
T cells and CD3
1 CD20 -T cells in patients with psoriasis and healthy donors. Human peripheral whole blood from patients with psoriasis and healthy donors was stained with anti-CD3, anti-CD20, anti-CD45RA, anti-C-C chemokine receptor type 7 (CCR7), anti-CD28, anti-CD27, anti-CD38, anti-CD62L, anti-CD69, anti-CD86, antihuman leucocyte antigen D-related (HLA-DR) and anti-CD40 antibodies or isotype controls. CD3
1
CD20
1
CD20
-T cell subpopulations were gated from the lymphocyte defined by a forward-scatter (FSC) and sidescatter (SSC) dot-plot, and the levels of CD45RA and CD3 1 CD20 -T cells from 10 patients with psoriasis. Data are expressed as the mean 6 standard error of the mean. *P < 0Á05; **P < 0Á01; ***P < 0Á001. -T cells with the PASI scores. P < 0Á05 was considered to be significant for correlation between the two groups. Table S1 . The clinical characteristics of patients with psoriasis
